This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01366/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01366/identifier/pubchem-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01366/identifier/pubchem-substance/
n9http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB01366/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01366/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01366
rdf:type
n3:Drug
n3:description
A long-acting beta-2-adrenergic receptor agonist. It is a potent bronchodilator that may be administered orally or by aerosol inhalation. [PubChem]
n3:group
approved
n3:indication
For the treatment of asthma and chronic obstructive pulmonary disease (COPD).
owl:sameAs
n8:DB01366 n9:DB01366
dcterms:title
Procaterol
adms:identifier
n13:46507907 n14:688561 n15:599984 n16:DB01366 n17:PA164748908
n3:mechanismOfAction
Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.
n3:synonym
SID26752069 SID11113915
n3:toxicity
Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor.
n3:synthesisReference
Mitsuji Akazawa, Teruo Hama, Yukio Kimura, Yoshinobu Yasuda, "Procaterol-containing preparation for application to the skin." U.S. Patent US5480649, issued February, 1989.
n3:IUPAC-Name
n4:271B42EE-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B42F4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B42F3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B42F0-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B42F1-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B42F2-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B42EC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B42ED-363D-11E5-9242-09173F13E4C5 n4:271B42EA-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B42EB-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:R03AC16 n6:R03CC08
n3:H-Bond-Acceptor-Count
n4:271B42FA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B42FB-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B42F5-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B42F6-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B42F8-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B42F7-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B42F9-363D-11E5-9242-09173F13E4C5
n3:absorption
Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
72332-33-3
n3:containedIn
n11:271B42E9-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4300-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4302-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4303-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B42FF-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B42FE-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4301-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B42EF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B42FC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B42FD-363D-11E5-9242-09173F13E4C5